{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:33:51Z","timestamp":1782286431196,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.aed.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T23:02:04Z","timestamp":1754521324000},"page":"194-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of Type 2 Amiodarone-Induced Thyrotoxicosis With a Combination of Low-Dose Prednisone and Bile Acid Resin to Attain Euthyroid State"],"prefix":"10.1016","volume":"12","author":[{"given":"Jasvin K.","family":"Manha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Spiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole O.","family":"Vietor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7437-5604","authenticated-orcid":false,"given":"Thanh D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed KM.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.aed.2025.07.011_bib1","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/archinte.160.12.1741","article-title":"Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, North American society of pacing and electrophysiology","volume":"160","author":"Goldschlager","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.aed.2025.07.011_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104521","article-title":"The role of amiodarone in contemporary management of complex cardiac arrhythmias","volume":"151","author":"Mujovi\u0107","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.aed.2025.07.011_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/105072501300176471","article-title":"The various effects of amiodarone on thyroid function","volume":"11","author":"Bogazzi","year":"2001","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.aed.2025.07.011_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486957","article-title":"2018 European thyroid association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction","volume":"7","author":"Bartalena","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"10","key":"10.1016\/j.aed.2025.07.011_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.aed.2025.07.011_bib6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jceh.2018.06.010","article-title":"INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids","volume":"8","author":"Arora","year":"2018","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.aed.2025.07.011_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000014","article-title":"Glucocorticoid-induced osteoporosis","volume":"1","author":"Briot","year":"2015","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.aed.2025.07.011_bib8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7326\/0003-4819-118-2-199301150-00006","article-title":"The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism","volume":"118","author":"Shakir","year":"1993","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.aed.2025.07.011_bib9","first-page":"3191","article-title":"Treatment of hyperthyroidism with a combination of methimazole and cholestyramine","volume":"81","author":"Mercado","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"33","key":"10.1016\/j.aed.2025.07.011_bib10","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1055\/s-2008-1068613","article-title":"Beschleunigte Elimination von Amiodaron durch Colestyramin","volume":"111","author":"Nitsch","year":"2008","journal-title":"DMW - Dtsch Med Wochenschr"},{"issue":"2","key":"10.1016\/j.aed.2025.07.011_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/hrt.79.2.121","article-title":"Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy","volume":"79","author":"Newman","year":"1998","journal-title":"Heart"},{"issue":"9053","key":"10.1016\/j.aed.2025.07.011_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.aed.2025.07.011_bib13","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1210\/endo-115-4-1605","article-title":"Amiodarone inhibits the conversion of thyroxine to triiodothyronine in isolated rat hepatocytes","volume":"115","author":"Aanderud","year":"1984","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.aed.2025.07.011_bib14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2004.11.028","article-title":"Amiodarone and the thyroid","volume":"118","author":"Basaria","year":"2005","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.aed.2025.07.011_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF03347021","article-title":"Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis","volume":"26","author":"Bogazzi","year":"2003","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"10.1016\/j.aed.2025.07.011_bib16","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1210\/jc.2010-0180","article-title":"Approach to the patient with amiodarone-induced thyrotoxicosis","volume":"95","author":"Bogazzi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.aed.2025.07.011_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-08-0348","article-title":"The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis","volume":"159","author":"Piga","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.aed.2025.07.011_bib18","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.7861\/clinmed.2021-0482","article-title":"Resistant type 2 amiodarone-induced thyrotoxicosis responsive to cholestyramine as an adjunctive therapy","volume":"21","author":"Rummaan","year":"2021","journal-title":"Clin Med (Lond)"},{"issue":"2","key":"10.1016\/j.aed.2025.07.011_bib19","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1210\/jc.2006-2059","article-title":"Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations","volume":"92","author":"Bogazzi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.aed.2025.07.011_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jc.2011-2390","article-title":"Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial","volume":"97","author":"Eskes","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.aed.2025.07.011_bib21","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2002-021874","article-title":"Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study","volume":"88","author":"Bogazzi","year":"2003","journal-title":"J Clin Endocrinol Metab"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915725000694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T11:27:04Z","timestamp":1758626824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915725000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S3050915725000694"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2025.07.011","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Type 2 Amiodarone-Induced Thyrotoxicosis With a Combination of Low-Dose Prednisone and Bile Acid Resin to Attain Euthyroid State","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}